-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ketamine One Teams Up With Cognetivity Neurosciences To Study PTSD, Depression
Ketamine One Teams Up With Cognetivity Neurosciences To Study PTSD, Depression
Ketamine One, a Canada-based health and wellness company focused on treatments for mental health, is teaming up with Cognetivity Neurosciences (OTC:CGNSF) for a collaborative study on treatments for PTSD and depression, the companies announced in a press release on Thursday.
Ketamine One specializes in ketamine-assisted therapy and psychedelic medicines. Cognetivity Neurosciences specializes in testing and tracking neurological activity in patients with cognitive impairments. Using Cognetivity's technology, Ketamine One will be able to better understand the impact of Ketamine One's treatments in patients.
The companies will run two different studies, one for depression and one for PTSD. These collaborative studies are the newest development in the partnership between the two companies. Ketamine One is already utilizing Cognetivity's technology in Ketamine One's North American clinical network after the two companies agreed on a commercial partnership earlier in the year.
"We're delighted to be extending our relationship with Cognetivity through this exciting new research project," said Adam Deffett, Interim CEO of Ketamine One. "Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America."
According to the press release, mental health disorders make up for 28% of the global burden of disability-adjusted life years among non-communicable diseases, outpacing cardiovascular diseases, and cancer.
"It's great to be working with Ketamine One on these clinical studies," Dr. Sina Habibi, CEO of Cognetivity said. "We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this huge market."
Ketamine One, a Canada-based health and wellness company focused on treatments for mental health, is teaming up with Cognetivity Neurosciences (OTC:CGNSF) for a collaborative study on treatments for PTSD and depression, the companies announced in a press release on Thursday.
氯胺酮1号,一家总部位于加拿大的专注于精神健康治疗的健康和健康公司正在与认知神经科学(场外交易代码:CGNSF)周四,两家公司在一份新闻稿中宣布,将进行一项关于创伤后应激障碍和抑郁症治疗的合作研究。
Ketamine One specializes in ketamine-assisted therapy and psychedelic medicines. Cognetivity Neurosciences specializes in testing and tracking neurological activity in patients with cognitive impairments. Using Cognetivity's technology, Ketamine One will be able to better understand the impact of Ketamine One's treatments in patients.
氯胺酮一号专攻氯胺酮辅助治疗和迷幻药物。认知神经科学公司专门测试和跟踪认知障碍患者的神经活动。使用Cognetivity的技术,氯胺酮一号将能够更好地了解氯胺酮一号治疗对患者的影响。
The companies will run two different studies, one for depression and one for PTSD. These collaborative studies are the newest development in the partnership between the two companies. Ketamine One is already utilizing Cognetivity's technology in Ketamine One's North American clinical network after the two companies agreed on a commercial partnership earlier in the year.
这两家公司将进行两项不同的研究,一个治疗抑郁症,一个治疗创伤后应激障碍。这些合作研究是两家公司合作的最新进展。今年早些时候,在两家公司达成商业合作伙伴关系后,氯胺酮一号已经在氯胺酮一号的北美临床网络中利用了Cognetivity的技术。
"We're delighted to be extending our relationship with Cognetivity through this exciting new research project," said Adam Deffett, Interim CEO of Ketamine One. "Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America."
他说:“我们很高兴通过这一令人兴奋的新研究项目扩大我们与Cognetivity的关系。”亚当·德菲特(Adam Deffett),氯胺酮一号的临时首席执行官。“可悲的是,抑郁症和创伤后应激障碍是非常常见的疾病,现有的治疗方法还有很多不尽如人意之处。在ICA的关键参与下,这项研究将进一步证明我们的疗法的威力,因为我们正在追求改变整个北美精神健康治疗方式的目标。”
According to the press release, mental health disorders make up for 28% of the global burden of disability-adjusted life years among non-communicable diseases, outpacing cardiovascular diseases, and cancer.
根据新闻稿,在非传染性疾病中,精神健康障碍占全球残疾调整寿命年负担的28%,超过心血管疾病和癌症。
"It's great to be working with Ketamine One on these clinical studies," Dr. Sina Habibi, CEO of Cognetivity said. "We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this huge market."
“很高兴能与氯胺酮一号合作进行这些临床研究。”西娜·哈比比博士,Cognetivity首席执行官表示。我们对获得有关使用ICA评估和监测抑郁症和创伤后应激障碍患者的高质量临床验证数据以及开发令人兴奋的新技术以更好地服务于这一巨大市场感到非常兴奋。“
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧